Corona Remedies Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Public

  • Employees
  • 5,686

Employees

  • Stock Symbol
  • CORONA

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $24.78
  • (As of Friday Closing)

Corona Remedies General Information

Description

Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • C, Mondeal Business Park
  • Near Gurudwara. S.G. Highway, Thaltej
  • Ahmedabad, Gujarat 380059
  • India
+91 079
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
NSE
Vertical(s)
Corporate Office
  • C, Mondeal Business Park
  • Near Gurudwara. S.G. Highway, Thaltej
  • Ahmedabad, Gujarat 380059
  • India
+91 079

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Corona Remedies Stock Performance

As of 13-Nov-2026, Corona Remedies’s stock price is $24.78. Its current market cap is $1.52B with 61.2M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$24.78 $25.00 $14.74 - $28.95 $1.52B 61.2M 45.8K $0.37

Corona Remedies Financials Summary

As of 30-Sep-2026, Corona Remedies has a trailing 12-month revenue of $168M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 1,349,933 1,003,791
Revenue 168,154 158,604 141,385 122,446
EBITDA 35,331 31,212 28,303 18,553
Net Income 22,328 20,950 17,672 10,932
Total Assets 129,800 127,727 108,706 99,597
Total Debt 11,989 17,472 10,082 19,061
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Corona Remedies Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Corona Remedies‘s full profile, request access.

Request a free trial

Corona Remedies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products
Pharmaceuticals
Ahmedabad, India
5,686 As of 2026

Bengaluru, India
 

Ahmedabad, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Corona Remedies Competitors (45)

One of Corona Remedies’s 45 competitors is Biocon, a Formerly PE-Backed company based in Bengaluru, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biocon Formerly PE-Backed Bengaluru, India
Torrent Pharmaceuticals Corporation Ahmedabad, India
Novartis Corporation Basel, Switzerland
Cipla Corporation Mumbai, India
GSK Corporation London, United Kingdom
You’re viewing 5 of 45 competitors. Get the full list »

Corona Remedies Patents

Corona Remedies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
FR-2704143-B1 Care bed on wheels. Inactive 21-Apr-1993
FR-2704143-A1 Treatment bed with castors Active 21-Apr-1993

Corona Remedies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Corona Remedies Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Corona Remedies‘s full profile, request access.

Request a free trial

Corona Remedies Investments (5)

Corona Remedies’s most recent deal was a Corporate Asset Purchase with Dr. Reddy's (Wokadine Brand) for . The deal was made on 30-Mar-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Dr. Reddy's (Wokadine Brand) 30-Mar-2026 Corporate Asset Purchase Buildings and Property
Bayer (Seven Pharmaceutical Brands in India) 16-Jul-2025 Buyout/LBO Buildings and Property
Sanofi India (Myoril Brand) 28-Jun-2023 Buyout/LBO Buildings and Property
Abbott India (Obimet and Thyrocab) 02-Apr-2018 Buyout/LBO Buildings and Property
GlaxoSmithKline (Dilo-BM, Dilo-DX, Stelbid and Vitneurin) 07-Mar-2017 Buyout/LBO Buildings and Property
To view Corona Remedies’s complete investments history, request access »

Corona Remedies ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Corona Remedies’s complete esg history, request access »

Corona Remedies FAQs

  • When was Corona Remedies founded?

    Corona Remedies was founded in 2004.

  • Where is Corona Remedies headquartered?

    Corona Remedies is headquartered in Ahmedabad, India.

  • What is the size of Corona Remedies?

    Corona Remedies has 5,686 total employees.

  • What industry is Corona Remedies in?

    Corona Remedies’s primary industry is Pharmaceuticals.

  • Is Corona Remedies a private or public company?

    Corona Remedies is a Public company.

  • What is Corona Remedies’s stock symbol?

    The ticker symbol for Corona Remedies is CORONA.

  • What is the current stock price of Corona Remedies?

    As of 13-Nov-2026 the stock price of Corona Remedies is $24.78.

  • What is the current market cap of Corona Remedies?

    The current market capitalization of Corona Remedies is $1.52B.

  • What is Corona Remedies’s current revenue?

    The trailing twelve month revenue for Corona Remedies is $168M.

  • Who are Corona Remedies’s competitors?

    Biocon, Torrent Pharmaceuticals, Novartis, Cipla, and GSK are some of the 45 competitors of Corona Remedies.

  • What is Corona Remedies’s annual earnings per share (EPS)?

    Corona Remedies’s EPS for 12 months was $0.37.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process